Novo Nordisk faces a suit claiming it failed to warn users of Ozempic of the danger of blindness. The suit is brought by a Maryland man who developed non-arteritic anterior ischemic optic neuropathy ...

More information: Alan Y. Hsu et al, Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy Risk Among Patients With Diabetes, JAMA Ophthalmology (2025). DOI: 10.1001/jamaophthalmol.2025.0349 ...

Considering taking supplements to treat ischemic optic neuropathy? Below is a list of common natural remedies used to treat or reduce the symptoms of ischemic optic neuropathy. Follow the links to ...

A Maryland man who took Ozempic and then became legally blind is suing the drug's manufacturer, arguing it had an obligation to warn patients that loss of sight could be a possible side effect. Todd ...

A Maryland man with diabetes is suing Novo Nordisk, alleging that semaglutide (Ozempic, Wegovy) made him blind due to nonarteritic anterior ischemic optic neuropathy. (NBC News) In a large study ...

Although only association and not causality can be inferred, this study showed that, among patients who had diabetes, an elevated risk of NAION was associated with semaglutide use compared with ...

Semaglutide use associated with increased risk for NAION at the two-, three-, and four-year time point from the index date. (HealthDay News) — For patients with diabetes, semaglutide use is ...

TUESDAY, April 8, 2025 (HealthDay News) -- For patients with diabetes, semaglutide use is associated with an increased risk for nonarteritic anterior ischemic optic neuropathy (NAION), according ...